A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

BACKGROUND: This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and clinical antitumour activity of tosedostat (CHR-2797), an orally bioavailable aminopeptidase inhibitor, in combination with paclitaxel. METHODS:...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: van Herpen, C M L, Eskens, F A L M, de Jonge, M, Desar, I, Hooftman, L, Bone, E A, Timmer-Bonte, J N H, Verweij, J
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2010
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2990605/
https://ncbi.nlm.nih.gov/pubmed/20877350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605917
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items